Equity strategy and market outlook – November 2021

Equity strategy and market outlook – November 2021

Published on 25 November 2021
Strategy

In this month’s strategy piece Alastair believes that global markets have rallied as investors take comfort from a benign Q3 earnings season and announcements from central banks which show that in private committee, policymakers seem more dovish than individual policymakers’ public comments suggest. The equity risk premium for global markets remains close to 15-year record lows while corporate credit spreads also remain low. This demonstrates a strong investor appetite for risk at present, even as risks build as economic growth moderates, real wage growth turns negative and China’s property sector remains in distress. Looking forward, we believe investors are not yet properly accounting for the possibility of a medium-term regime change in respect of inflation. Fiscal policy could supersede monetary policy as the primary mode of stimulus in the next downturn. Constrained by above-target inflation, central banks may no longer be best placed to stimulate the economy when required. A higher inflation, fiscally driven economic regime is likely to engender lower market valuations and outperformance of old economy sectors able to offset rising input costs by increasing prices. This process may have already started, with banks and energy leading global sector rankings in 2021 year to date. We remain cautious on global equities as current risk premia are low and we expect forward returns to normalise over the course of 2022 as monetary policy settings become less accommodative. Furthermore, the prospect of a significant sector rotation is increasing in probability as investors start to discount a sustained period of above-target inflation.

Download PDF

Latest

Industrials | thematic

Edison explains: Europe’s ageing buildings

Consumer | thematic

Stock of the month – PZ Cussons

thematic

Edison explains: The return of gold M&A

thematic

The new retail investors: A portrait

Healthcare

Artificial intelligence in drug discovery

Continue Reading
Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.